Transforming growth factor beta 1 as a biomarker for prostate cancer.
Transforming growth factor beta 1 as a biomarker for prostate cancer.
复制标题
将生长因子β1 转化为前列腺癌的生物标志物。
DOI：
10.1002/jcb.240501212
复制
发表时间：
1992
期刊：
影响因子：
--
通讯作者：
Park,SH
中科院分区：
文献类型：
--
作者：
Thompson,TC;Truong,LD;Timme,TL;Kadmon,D;McCune,BK;Flanders,KC;Scardino,PT;Park,SH
使用小鼠前列腺重建（MPR）模型系统，在通过重组逆转录病毒将thras和myconcogenes引入尿生殖窦的间充质和上皮区室的条件下，使用近交系C57 BL/6小鼠以高频率（>90%）产生低分化前列腺癌。北方印迹和免疫组化分析表明，从良性前列腺增生（BPH）到前列腺癌的转变总是与诱导转化生长因子-β1（TGF-β1）表达升高有关。对人BPH和前列腺癌中TGF-β1的类似分析与我们的MPR结果一致，并表明与正常或良性前列腺组织相比，前列腺癌中细胞外TGF-β1的积累明显更强烈。有趣的是，当在良性前列腺上皮存在的情况下在前列腺基质中观察到良性病理时，细胞外TGF-β1主要见于基质室中。实验研究清楚地表明，前列腺癌细胞中TGF-β1和其他生长相关基因的mRNA水平受到雄激素的调节。总体而言，我们的研究结果表明，TGF-β1升高参与前列腺癌的发展。直接测定TGF-β1水平和分布以及分析TGF-β1产生的局部和全身效应可能是前列腺癌的有用生物标志物。© 1992 Wiley利斯公司
Using the mouse prostate reconstitution (MPR) model system, under conditions where therasandmyconcogenes are introduced via a recombinant retrovirus into both the mesenchymal and epithelial compartments of the urogenital sinus, poorly differentiated prostate cancer is produced with high frequency (>90%) using inbred C57BL/6 mice. Northern blotting and immunohistochemical analysis showed that the transition from benign prostatic hyperplasia (BPH) to prostate cancer is invariably associated with the induction of elevated transforming growth factor‐β1 (TGF‐β1) expression. Similar analysis of TGF‐β1 in human BPH and prostate cancer is consistent with our MPR results and indicates that the accumulation of extracellular TGF‐β1 is significantly more intense in prostate cancer compared to normal or benign prostate tissues. Interestingly, where benign pathologies are observed in the prostatic stroma in the presence of benign prostatic epithelium, extracellular TGF‐β1 is seen predominantly in the stromal compartment. Experimental studies clearly demonstrate that mRNA levels of TGF‐β1 and other growth related genes are regulated by androgens in prostate cancer cells. Overall, our results suggest that elevated TGF‐β1 is involved in the development of prostate cancer. Direct determination of TGF‐β1 levels and distribution as well as analysis of localized and systemic effects produced by TGF‐β1 may serve as useful biomarkers for prostate cancer. © 1992 Wiley‐Liss, Inc.